

Supplemental Materials

Inflammatory Response and Exosome Biogenesis of Choroid Plexus Organoids Derived from Human Pluripotent Stem Cells

Laureana Muok¹, Chang Liu¹, Xingchi Chen¹, Colin Esmonde¹, Peggy Arthur²,

Xueju Wang³, Mandip Singh², Tristan Driscoll¹, Yan Li^{1,*}


1. Department of Chemical and Biomedical Engineering, FAMU-FSU College of Engineering, Florida State University, Tallahassee, FL 32310, USA

2. College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA

3. Department of Materials Science and Engineering, University of Connecticut, Storrs, CT 06268, USA


* Correspondence: yli4@fsu.edu

Supplemental Figure S1. The aggregate size image analysis (day 3, 7, 11, 16, 21, 28). The growth conditions were the same for CHIR+ and CHIR- conditions during day 0-11 before CHIR was added to the culture media.




Supplemental Figure S2. The amount of mRNA isolated for CHIR- and CHIR+ conditions. The differentiation was initiated with the same number of the cells for the two conditions. The difference in spheroid number was evident after CHIR was added to the culture compared to no CHIR was used. The organoids from the same number of wells were used for mRNA isolation, which should come from the same number of cells at day 0. The results from three experiments were shown (Exp 1, 2, and 3).


Exp 1



Exp 2




Exp 3




Isolated mRNA	CHIR+/CHIR- ratio
Exp 1	1.87
Exp 2	2.26
Exp 3	1.32
Mean±SD	1.82±0.47
Exp 3-Abeta	0.87



Supplemental Figure S3. The Live/Dead assay images for the replated organoids to support Figure 2A. The scale bar: 50 μ m.




Supplemental Figure S4. Example of SSC vs. FSC plot to show flow cytometry gating strategy for Figure 2.



Supplemental Figure S5. The schematic illustration of extracellular vesicle isolation procedure. Christopher Jean-Baptiste prepared the schematic illustration of exosome isolation using BioRender.



Supplemental Figure S6. Zeta potential of ChP organoid-secreted extracellular vesicles determined by ZetaView.



Supplemental Table S1. Normalization of EV number to the isolated mRNA amount.

Parameters	CHIR-	CHIR+	CHIR+/CHIR- ratio
EV number	$7.8 \pm 2.6 \times 10^7$ per mL	$12.6 \pm 2.7 \times 10^7$ per mL	1.62
mRNA amount	271 ng/ μ L (mg/mL)	508 ng/ μ L (mg/mL)	1.87
EV/mRNA	$2.88 \pm 0.96 \times 10^5$ /mg	$2.48 \pm 0.53 \times 10^5$ /mg	0.86\pm0.15

Supplemental Table S2. ChP marker analysis for mRNA-Seq in Song et al (2019) study [39].

Transcriptome Analysis of ChP Markers in cortical organoids. 3D forebrain organoids containing isogenic microglia-like cells (DMG) vs. microglia-like cells only (MG). the changes are expressed as Log2(DMG/MG). A positive value means upregulation in DMG group.

The meaning of these markers are explained in the main text.

GeneName	baseMean	log2FoldChange
DCN	32827.22	3.1730
LUM	35876.97	2.7775
IGFBP7	232.5938	2.2776
TTR	2570.966	1.7943
CLIC6	23.89272	1.6367
MSX1	1182.936	1.4409
PLTP	7230.866	1.4052
AQP1	30424.8	1.1713
DLK1	5533.424	0.8398
PLEC	7382.984	0.4296

The expression of tight junction markers: TJP1/2, CLDNs, OCLN, MPDZ; specific transporters involved in nutrient trafficking: SLC46A1, SLC23A2. Clinically relevant markers: SERPINF1-serpin family F member; PARK7-Parkinsonism associated deglycase. OTX2- early transcription factor involved in ChP development.

GeneName	baseMean	log2FoldChange
SERPINF1	3889.831	2.3839
TJP2	726.8553	1.6434
SLC46A1	170.2765	1.5218
TJP1	1701.744	0.7481
CLDN5	23.0293	0.5514
OCLN	161.7074	0.1442
PARK7	2734.893	0.0742
RSPO3	755.9327	0.0302
INADL	505.462	0.0231
MPDZ	1256.236	-0.1027
SLC23A2	1138.679	-0.1837
CLDN3	91.25794	-0.5217
CLDN1	120.5591	-1.4768
CA2	343.5995	-2.1864
HTR2C	27.34546	-6.2390
OTX2	689.1214	-9.1203

Ciliary markers-CCDC67, ARL13B; Ciliary transcription factor: FOXJ1

Brain-derived factor-secretogranin-1 (CHGB), a neuro-endocrine secretory protein; NDRG2, an astrocyte-expressed protein that plays a role in neurite growth. C1R-complement protein. KRT17-keratin 17; TAGLIN-transgelin, expressed in a subset of cells in epithelium.

RBPs: retinol binding proteins, the more mature markers expressed in dark cells of ChP epithelium. IGF2: restricted in dark cells of ChP epithelium.

LGALS3BP: human-specific developmental secreted protein.

GeneName	baseMean	log2FoldChange
CHGB	1920.537	2.4160
C1R	737.2601	2.3750
NDRG2	1456.452	1.5622
CCDC67	9.219291	0.9642
TAGLN	568.3037	0.9241
ARL13B	222.5634	0.1401
KRT17	5.476122	-0.4263
FOXJ1	138.8025	-4.1214
GeneName	baseMean	log2FoldChange
RBP4	661.1704	2.5971
MDK	11336.73	2.3416
RBP3	29.90876	2.2582
LGALS3BP	6305.362	2.2219
IGF2	37271.79	2.1672
RBP2	68.89518	1.2927
RBP1	557.7267	0.9952
PRAP1	10.72332	0.0833

Supplemental Table S3. A list of antibodies.

Cells	Primary Antibody	Origin/ Isotype	Supplier/ Cat#	Dilution
ChP markers	TTR	Mouse IgG1	Abcam, ab204997	1:200
	CLIC6	Rabbit IgG	Abcam, ab204566	1:500
Neuronal cells	Beta-tubulin III	Mouse IgG1	Millipore, MAB1637	1:100
Secondary	Alexa Fluor 488, goat anti-mouse IgG1	-	ThermoFisher, A-21121	1:200
	Alexa Fluor 488 Goat Anti-rabbit IgG		ThermoFisher, A-11008	1:200

Supplemental Table S4. Primer sequence for the target genes determined by RT-PCR.

Primer number	Gene name	Primer name in database	Primer sequence (5'-3')
1	ACTB	Bactin F	GTACTCCGTGTGGATCGGCG
		Bactin R	AAGCATTGCGGTGGACGATGG
2	GAPDH	GAPDH-F	TCACTGCCACCCAGAAGACTG
		GAPDH-R	GGATGACCTTGCCCACAGC
3	CLIC6	CLIC6-F1	GCAGTTTTACCCCAGCAGTCA
		CLIC6-R1	AATCTGCCCCCTAACCAGATG
4	PLEC	PLEC-F1	CTGTAGAGGGCCCTGGTGT
		PLEC-R1	GGGGCTTCTCTGGGTAGACTG
5	PLTP	PLTP-F1	CCCTGACTGAGAGGAAGTGA
		PLTP-R1	TCCATGGCAGAGTCGAAGAAG
6	TTR	TTR-F1	TGGGAAAACCACTGAGTCTGG
		TTR-R1	GATGCCAAGTGCCTTCCAGTA
7	IGFBP7	IGFBP7-F1	GGAACAAGGTAAAAAGGGGTCA
		IGFBP7-R1	AGCACCCAGCCAGTTACTTCA
8	MSX1	MSX1-F1	GCCTTCCCTTTAACCCTCACA
		MSX1-R1	GGGACTCTTCCAGCCACTTTT
9	DCN	DCN-F1	GATTGTTGGTGGGAGGCACTAT
		DCN-R1	GCCTCCTTTATGCCAACCTGT
10	LUM	LUM-F1	GGCAGGCCTATTCATCACAA
		LUM-R1	AAGGTTTTGCACATCATTTGACAG
11	DLK	DLK1-F1	CTGAGAGTGTCTGGGATCCTTG
		DLK1-R1	TGGATCGCTGTCTTTGAGCTT
12	AQP1	AQP1-F1	CAGCCCAAGGACAGTTCAGAG
		AQP1-R1	TCATGGCTAAGTGCACAGTGG
13	TNF α	Forward	TGGCCAATGGCGTGGAGCTG
		Reverse	GTAGGAGACGGCGATGCGGC
14	IL-6	Forward	GAAGCTCTTCTCCACAAGCG
		Reverse	TTTTCTGCCAGTGCCTCTTT
15	IL-12 β	Forward	CCAAGGGGTGACGTGCGGAG
		Reverse	GGTGGGTCAGGTTTGATGATGTCCC
16	CD163	Forward	CCAGTCCCAAACACTGTCCT
		Reverse	ATGCCAGTGAGCTTCCCGTTCAGC
17	TGF β	Forward	CCTACATTTGGAGCCTGGAC
		Reverse	TGTCCTTAAATACAGCCCCC
18	IL-10	Forward	AAGCCTGACCACGCTTTCTA
		Reverse	ATGAAGTGGTTGGGGAATGA
19	SMPD2-1	SMPD2-F1	GCCTGGGAGACTTTCTGAACC
		SMPD2-R1	AAGTGGTGTGCAGCTGGGTAG
20	SRSF5(hrs)-1	SRSF5-F1	CTTCTCGGATCGAGGCTTCTT
		SRSF5-R1	TCGAATCAACTGCGCTCATTA

21	TSG101	TSG101 F	CACCTGGTGGTCCATATCCTG
		TSG101 R	GATGGTGTCCCTCGCTGATTGT
22	STAM1	STAM1-F1	CACTGGATTTTTGGGTTGCTC
		STAM1-R1	GTGGAAAACATTTTTTCGCATGA
23	PDCD61P (ALIX)	PDCD61P F	TAAGTGCATCTGAGGGCCAAA
		PDCD61P R	GGGGCCTCCTTTCCTAGTTTC
24	PDCD61Pi4 (ALIXI4)	PDCD61Pi4 F	TTGGCTAATCAGGCTGCAGAT
		PDCD61Pi4 R	TCACATGCAAAGTAAGCAAGTGTT
25	MITF-1	MITF-F1	GAATTGGTGATGGGTGATGGA
		MITF-R1	TGCATGGGAACATATGCAGTTG
26	RAB27B	RAB27B F	TCCATGAAGCTGCTTGTCTCA
		RAB27B R	GTTGGGTCTCCACCCAGAAAT
27	MMP2	MMP2 F1	CATCGCTCAGATCCGTGGTG
		MMP2 R1	GCATCAATCTTTTCCGGGAGC
28	MMP3	MMP3 F1	CCATCTCTTCCTTCAGGCGT
		MMP3 R1	ATGCCTCTTGGGTATCCAGC
29	MMP9	MMP9-F	GGCCACTACTGTGCCTTTGAG
		MMP9-R	AATCGCCAGTACTTCCCATCC